Molecular functions of syndecan-1 in disease

Matrix Biology

Volumn 31, Issue 1, 2012, Pages 3-16

  Teng, Yvonne Hui Fang ^a   Aquino, Rafael S ^a   Park, Pyong Woo ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer; Heparan sulfate; Infection; Inflammation; Proteoglycan; Syndecan

Indexed keywords

BLEOMYCIN; CAPSID PROTEIN L1; CHEMOKINE; DEXTRAN SULFATE; GLYPICAN 1; INTEGRIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; OXAZOLONE; SCATTER FACTOR; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE LUNG INJURY; APOPTOSIS; ARTERY INJURY; ARTHRITIS; ATHEROSCLEROSIS; BREAST CANCER; CELL ADHESION; CELL STRAIN MCF 7; CHLAMYDIA TRACHOMATIS; COLITIS; COLON CANCER; DISEASE COURSE; EDEMA; ENDOCARDITIS; ENDOTHELIUM CELL; GENE SILENCING; HEPATITIS E VIRUS; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATORY DISEASE; LEUKOCYTE; LUNG DISEASE; LUNG LAVAGE; METASTASIS; MOLECULAR BIOLOGY; MYELOMA; NEOPLASM; NEUTROPHIL; NONHUMAN; OSTEOMYELITIS; OVARY CANCER; PANCREAS CANCER; PAPILLOMAVIRUS INFECTION; PLASMA CELL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SEXUALLY TRANSMITTED DISEASE; SKIN ALLERGY; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TH2 CELL; TISSUE INJURY; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS VIRULENCE;

ANIMALS; INFECTION; INFLAMMATION; MICE; MICE, KNOCKOUT; NEOPLASMS; SYNDECAN-1;

MUS;

EID: 84855578074     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2011.10.001     Document Type: Review

References (188)

1. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 2000, 25:329-332.
2. Anttonen A., Kajanti M., Heikkila P., Jalkanen M., Joensuu H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br. J. Cancer 1999, 79:558-564.
3. Anttonen A., Heikkila P., Kajanti M., Jalkanen M., Joensuu H. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 2001, 32:297-305.
4. Argyris E.G., Acheampong E., Nunnari G., Mukhtar M., Williams K.J., Pomerantz R.J. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J. Virol. 2003, 77:12140-12151.
5. Bacsa S., Karasneh G., Dosa S., Liu J., Valyi-Nagy T., Shukla D. Syndecan-1 and syndecan-2 play key roles in herpes simplex virus type-1 infection. J. Gen. Virol. 2011, 92:733-743.
6. Bao X., Moseman E.A., Saito H., Petryniak B., Thiriot A., Hatakeyama S., Ito Y., Kawashima H., Yamaguchi Y., Lowe J.B., von Andrian U.H., Fukuda M. Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. Immunity 2010, 33:817-829.
7. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M.G., Pecciarini L., Angelo Mauri F., Veronese S., Caffo O., Lucenti A., Palma P.D., Galligioni E., Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003, 98:474-483.
8. Bartlett A.H., Park P.W. Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications. Expert. Rev. Mol. Med. 2010, 12:e5.
9. Bartlett A.H., Hayashida K., Park P.W. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol. Cells 2007, 24:153-166.
10. Beauvais D.M., Ell B.J., McWhorter A.R., Rapraeger A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 2009, 206:691-705.
11. Beiting D.P., Park P.W., Appleton J.A. Synthesis of syndecan-1 by muscle cells is an early response to infection with Trichinella spiralis but is not essential for larval development or immune modulation. Infect. Immun. 2006, 74:1941-1943.
12. Bernfield M., Kokenyesi R., Kato M., Hinkes M.T., Spring J., Gallo R.L., Lose E.J. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 1992, 8:365-393.
13. Bernfield M., Götte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
14. Bhanot P., Nussenzweig V. Plasmodium yoelii sporozoites infect syndecan-1 deficient mice. Mol. Biochem. Parasitol. 2002, 123:143-144.
15. Bingley J.A., Hayward I.P., Campbell J.H., Campbell G.R. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J. Vasc. Surg. 1998, 28:308-318.
16. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
17. Blackwood L.L., Stone R.M., Iglewski B.H., Pennington J.E. Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect. Immun. 1983, 39:198-201.
18. Bobardt M.D., Saphire A.C., Hung H.C., Yu X., Van der Schueren B., Zhang Z., David G., Gallay P.A. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003, 18:27-39.
19. Bode L., Salvestrini C., Park P.W., Li J., Esko J.D., Yamaguchi Y., Murch S., Freeze H.H. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal barrier function. J. Clin. Invest. 2008, 118:229-238.
20. Brule S., Charnaux N., Sutton A., Ledoux D., Chaigneau T., Saffar L., Gattegno L. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006, 16:488-501.
21. Bucior I., Mostov K., Engel J.N. Pseudomonas aeruginosa-mediated damage requires distinct receptors at the apical and basolateral surfaces of the polarized epithelium. Infect. Immun. 2010, 78:939-953.
22. Carey D.J., Evans D.M., Stahl R.C., Asundi V.K., Conner K.J., Garbes P., Cizmeci-Smith G. Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan. J. Cell Biol. 1992, 117:191-201.
23. Ceballos A., Remes Lenicov F., Sabatte J., Rodriguez Rodrigues C., Cabrini M., Jancic C., Raiden S., Donaldson M., Agustin Pasqualini R., Marin-Briggiler C., Vazquez-Levin M., Capani F., Amigorena S., Geffner J. Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. J. Exp. Med. 2009, 206:2717-2733.
24. Charnaux N., Brule S., Chaigneau T., Saffar L., Sutton A., Hamon M., Prost C., Lievre N., Vita C., Gattegno L. RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology 2005, 15:119-130.
25. Chen L., Klass C., Woods A. Syndecan-2 regulates transforming growth factor-beta signaling. J. Biol. Chem. 2004, 279:15715-15718.
26. Chen Y., Hayashida A., Bennett A.E., Hollingshead S.K., Park P.W. Streptococcus pneumoniae sheds syndecan-1 ectodomains through ZmpC, a metalloproteinase virulence factor. J. Biol. Chem. 2007, 282:159-167.
27. Christensen J.G., Burrows J., Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005, 225:1-26.
28. Chung M.C., Popova T.G., Millis B.A., Mukherjee D.V., Zhou W., Liotta L.A., Petricoin E.F., Chandhoke V., Bailey C., Popov S.G. Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J. Biol. Chem. 2006, 281:31408-31418.
29. Couchman J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26:89-114.
30. David G., van der Schueren B., Marynen P., Cassiman J.J., van den Berghe H. Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells. J. Cell Biol. 1992, 118:961-969.
31. Day R., Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 1999, 354:62-65.
32. Day P.M., Gambhira R., Roden R.B., Lowy D.R., Schiller J.T. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J. Virol. 2008, 82:4638-4646.
33. de Witte L., Bobardt M., Chatterji U., Degeest G., David G., Geijtenbeek T.B., Gallay P. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19464-19469.
34. Derksen P.W., Keehnen R.M., Evers L.M., van Oers M.H., Spaargaren M., Pals S.T. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99:1405-1410.
35. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
36. Dews I.C., Mackenzie K.R. Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20782-20787.
37. Dias-Baruffi M., Pereira-da-Silva G., Jamur M.C., Roque-Barreira M.C. Heparin potentiates in vivo neutrophil migration induced by IL-8. Glycoconj. J. 1998, 15:523-526.
38. Ding K., Lopez-Burks M., Sanchez-Duran J.A., Korc M., Lander A.D. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J. Cell Biol. 2005, 171:729-738.
39. Echtermeyer F., Streit M., Wilcox-Adelman S., Saoncella S., Denhez F., Detmar M., Goetinck P. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J. Clin. Invest. 2001, 107:R9-R14.
40. Echtermeyer F., Bertrand J., Dreier R., Meinecke I., Neugebauer K., Fuerst M., Lee Y.J., Song Y.W., Herzog C., Theilmeier G., Pap T. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat. Med. 2009, 15:1072-1076.
41. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M., Sato H. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 2003, 278:40764-40770.
42. Fears C.Y., Woods A. The role of syndecans in disease and wound healing. Matrix Biol. 2006, 25:443-456.
43. Fears C.Y., Gladson C.L., Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J. Biol. Chem. 2006, 281:14533-14536.
44. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Biol. 2000, 148:811-824.
45. Floer M., Gotte M., Wild M.K., Heidemann J., Gassar E.S., Domschke W., Kiesel L., Luegering A., Kucharzik T. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am. J. Pathol. 2010, 176:146-157.
46. HSPG-expressing Neisseria gonorrhoeae into epithelial cells. Cell. Microbiol. 2000, 2:69-82.
47. Fritchley S.J., Kirby J.A., Ali S. The antagonism of interferon-gamma (IFN-gamma) by heparin: examination of the blockade of class II MHC antigen and heat shock protein-70 expression. Clin. Exp. Immunol. 2000, 120:247-252.
48. Fukai N., Kenagy R.D., Chen L., Gao L., Daum G., Clowes A.W. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1356-1362.
49. Fuki I.V., Kuhn K.M., Lomazov I.R., Rothman V.L., Tuszunski G.P., Iozzo R.V., Swenson T.L., Fisher E.A., Williams K.J. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 1997, 100:1611-1622.
50. Gama-de-Souza L.N., Cyreno-Oliveira E., Freitas V.M., Melo E.S., Vilas-Boas V.F., Moriscot A.S., Jaeger R.G. Adhesion and protease activity in cell lines from human salivary gland tumors are regulated by the laminin-derived peptide AG73, syndecan-1 and beta1 integrin. Matrix Biol. 2008, 27:402-419.
51. Girgis D.O., Sloop G.D., Reed J.M., O'Callaghan R.J. Effects of toxin production in a murine model of Staphylococcus aureus keratitis. Invest. Ophthalmol. Vis. Sci. 2005, 46:2064-2070.
52. Gould S.E., Upholt W.B., Kosher R.A. Syndecan 3: a member of the syndecan family of membrane-intercalated proteoglycans that is expressed in high amounts at the onset of chicken limb cartilage differentiation. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:3271-3275.
53. Grassmé H., Gulbins E., Brenner B., Ferlinz K., Sandhoff K., Harzer K., Lang F., Meyer T.F. Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 1997, 91:605-615.
54. Grootjans J.J., Zimmermann P., Reekmans G., Smets A., Degeest G., Durr J., David G. Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13683-13688.
55. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
56. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Proudfoot A.E. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu. Rev. Biochem. 2005, 74:385-410.
57. Hashimoto Y., Skacel M., Adams J.C. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 2008, 8:185.
58. Hayashi K., Hayashi M., Jalkanen M., Firestone J.H., Trelstad R.L., Bernfield M. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J. Histochem. Cytochem. 1987, 35:1079-1088.
59. Hayashida K., Johnston D.R., Goldberger O., Park P.W. Syndecan-1 expression in epithelial cells is induced by TGF-beta through a PKA-dependent pathway. J. Biol. Chem. 2006, 281:24365-24374.
60. Hayashida K., Chen Y., Bartlett A.H., Park P.W. Syndecan-1 is an in vivo suppressor of Gram-positive toxic shock. J. Biol. Chem. 2008, 283:19895-19903.
61. Hayashida K., Stahl P.D., Park P.W. Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5. J. Biol. Chem. 2008, 283:35435-35444.
62. Hayashida A., Bartlett A.H., Foster T.J., Park P.W. Staphylococcus aureus beta-toxin induces acute lung injury through syndecan-1. Am. J. Pathol. 2009, 174:509-518.
63. Hayashida K., Parks W.C., Park P.W. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 2009, 114:3033-3043.
64. Hayashida K., Bartlett A.H., Chen Y., Park P.W. Molecular and cellular mechanisms of ectodomain shedding. Anat. Rec. 2010, 293:925-937.
65. Hayashida A., Amano S., Park P.W. Syndecan-1 promotes Staphylococcus aureus corneal infection by counteracting neutrophil-mediated host defense. J. Biol. Chem. 2011, 285:3288-3297.
66. Haynes A., Ruda F., Oliver J., Hamood A.N., Griswold J.A., Park P.W., Rumbaugh K.P. Syndecan-1 shedding contributes to Pseudomonas aeruginosa sepsis. Infect. Immun. 2005, 73:7914-7921.
67. Haywood-Watson R.J., Holcomb J.B., Gonzalez E.A., Peng Z., Pati S., Park P.W., Wang W., Zaske A.M., Menge T., Kozar R.A. Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation. PLoS One 2011, 6:e23530.
68. Henry-Stanley M.J., Hess D.J., Erlandsen S.L., Wells C.L. Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier. Shock 2005, 24:571-576.
69. Henry-Stanley M.J., Zhang B., Erlandsen S.L., Wells C.L. Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on enterocyte shedding of syndecan-1 and associated decreases in internalization of Listeria monocytogenes and Staphylococcus aureus. Cytokine 2006, 34:252-259.
70. Hu Y., Sun H., Owens R.T., Gu Z., Wu J., Chen Y.Q., O'Flaherty J.T., Edwards I.J. Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia 2010, 12:826-836.
71. Hughes F.J., Howells G.L. Interleukin-11 inhibits bone formation in vitro. Calcif. Tissue Int. 1993, 53:362-364.
72. Hynes R.O., Lively J.C., McCarty J.H., Taverna D., Francis S.E., Hodivala-Dilke K., Xiao Q. The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb. Symp. Quant. Biol. 2002, 67:143-153.
73. Iba K., Albrechtsen R., Gilpin B., Frohlich C., Loechel F., Zolkiewska A., Ishiguro K., Kojima T., Liu W., Langford J.K., Sanderson R.D., Brakebusch C., Fassler R., Wewer U.M. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J. Cell Biol. 2000, 149:1143-1156.
74. Ikesue M., Matsui Y., Ohta D., Danzaki K., Ito K., Kanayama M., Kurotaki D., Morimoto J., Kojima T., Tsutsui H., Uede T. Syndecan-4 deficiency limits neointimal formation after vascular injury by regulating vascular smooth muscle cell proliferation and vascular progenitor cell mobilization. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1066-1074.
75. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell Mol. Med. 2011, 15:1013-1031.
76. Ishiguro K., Kadomatsu K., Kojima T., Muramatsu H., Iwase M., Yoshikai Y., Yanada M., Yamamoto K., Matsushita T., Nishimura M., Kusugami K., Saito H., Muramatsu T. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J. Biol. Chem. 2001, 276:47483-47488.
77. Ishikawa T., Kramer R.H. Sdc1 negatively modulates carcinoma cell motility and invasion. Exp. Cell. Res. 2010, 316:951-965.
78. Jalkanen M., Rapraeger A., Saunders S., Bernfield M. Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain. J. Cell. Biol. 1987, 105:3087-3096.
79. Jiang D., Liang J., Campanella G.S., Guo R., Yu S., Xie T., Liu N., Jung Y., Homer R., Meltzer E.B., Li Y., Tager A.M., Goetinck P.F., Luster A.D., Noble P.W. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J. Clin. Invest. 2010, 120:2049-2057.
80. Joensuu H., Anttonen A., Eriksson M., Makitaro R., Alfthan H., Kinnula V., Leppa S. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 2002, 62:5210-5217.
81. Juuti A., Nordling S., Lundin J., Louhimo J., Haglund C. Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology 2005, 68:97-106.
82. Kainulainen V., Wang H., Schick C., Bernfield M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 1998, 273:11563-11569.
83. Kalia M., Chandra V., Rahman S.A., Sehgal D., Jameel S. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J. Virol. 2009, 83:12714-12724.
84. Kato M., Saunders S., Nguyen H., Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol. Biol. Cell 1995, 6:559-576.
85. Kato M., Wang H., Kainulainen V., Fitzgerald M.L., Ledbetter S., Ornitz D.M., Bernfield M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 1998, 4:691-697.
86. Kharabi Masouleh B., Ten Dam G.B., Wild M.K., Seelige R., van der Vlag J., Rops A.L., Echtermeyer F.G., Vestweber D., van Kuppevelt T.H., Kiesel L., Gotte M. Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity. J. Immunol. 2009, 182:4985-4993.
87. Khotskaya Y.B., Dai Y., Ritchie J.P., MacLeod V., Yang Y., Zinn K., Sanderson R.D. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 2009, 284:26085-26095.
88. Kim C.W., Goldberger O.A., Gallo R.L., Bernfield M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol. Biol. Cell 1994, 5:797-805.
89. Kiviniemi J., Kallajoki M., Kujala I., Matikainen M.T., Alanen K., Jalkanen M., Salmivirta M. Altered expression of syndecan-1 in prostate cancer. APMIS 2004, 112:89-97.
90. Kjellen L., Pettersson I., Hook M. Cell-surface heparan sulfate: an intercalated membrane proteoglycan. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:5371-5375.
91. Klass C.M., Couchman J.R., Woods A. Control of extracellular matrix assembly by syndecan-2 proteoglycan. J. Cell Sci. 2000, 113:493-506.
92. Kliment C.R., Oury T.D. Extracellular superoxide dismutase protects cardiovascular syndecan-1 from oxidative shedding. Free Radic. Biol. Med. 2011, 50:1075-1080.
93. Kliment C.R., Tobolewski J.M., Manni M.L., Tan R.J., Enghild J., Oury T.D. Extracellular superoxide dismutase protects against matrix degradation of heparan sulfate in the lung. Antioxid. Redox.Signal 2008, 10:261-268.
94. Kliment C.R., Englert J.M., Gochuico B.R., Yu G., Kaminski N., Rosas I., Oury T.D. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J. Biol. Chem. 2009, 284:3537-3545.
95. Koda J.E., Rapraeger A., Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells. Cell surface proteoglycan as a receptor for interstitial collagens. J. Biol. Chem. 1985, 260:8157-8162.
96. Kojima T., Shworak N.W., Rosenberg R.D. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J. Biol. Chem. 1992, 267:4870-4877.
97. Kon S., Ikesue M., Kimura C., Aoki M., Nakayama Y., Saito Y., Kurotaki D., Diao H., Matsui Y., Segawa T., Maeda M., Kojima T., Uede T. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J. Exp. Med. 2008, 205:25-33.
98. Koppel H., Yard B.A., Christ M., Wehling M., van der Woude F.J. Modulation of angiotensin II-mediated signalling by heparan sulphate glycosaminoglycans. Nephrol. Dial. Transplant. 2003, 18:2240-2247.
99. Kuschert G.S., Coulin F., Power C.A., Proudfoot A.E., Hubbard R.E., Hoogewerf A.J., Wells T.N. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999, 38:12959-12968.
100. Kusumoto T., Kodama J., Seki N., Nakamura K., Hongo A., Hiramatsu Y. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol. Rep. 2010, 23:917-925.
101. Lambaerts K., Wilcox-Adelman S.A., Zimmermann P. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr. Opin. Cell Biol. 2009, 21:662-669.
102. Lantz M., Thysell H., Nilsson E., Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J. Clin. Invest. 1991, 88:2026-2031.
103. Laquerre S., Argnani R., Anderson D.B., Zucchini S., Manservigi R., Glorioso J.C. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J. Virol. 1998, 72:6119-6130.
104. Lekstrom-Himes J.A., Gallin J.I. Immunodeficiency diseases caused by defects in phagocytes. N. Engl. J. Med. 2000, 343:1703-1714.
105. Lemjabbar H., Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. 2002, 8:41-46.
106. Lendorf M.E., Manon-Jensen T., Kronqvist P., Multhaupt H.A., Couchman J.R. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J. Histochem. Cytochem. 2011, 59:615-629.
107. Lenz D., Hambsch J., Schneider P., Hausler H.J., Sauer U., Hess J., Tarnok A. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?. Crit. Care 2003, 7:185-190.
108. Li Q., Park P.W., Wilson C.L., Parks W.C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646.
109. Liu D., Shriver Z., Venkataraman G., El Shabrawi Y., Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2002, 99:568-573.
110. Liu J., Shriver Z., Pope R.M., Thorp S.C., Duncan M.B., Copeland R.J., Raska C.S., Yoshida K., Eisenberg R.J., Cohen G., Linhardt R.J., Sasisekharan R. Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J. Biol. Chem. 2002, 277:33456-33467.
111. Liu B.Y., McDermott S.P., Khwaja S.S., Alexander C.M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4158-4163.
112. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003, 4:140-156.
113. Lortat-Jacob H., Grosdidier A., Imberty A. Structural diversity of heparan sulfate binding domains in chemokines. Proc. Natl. Acad. Sci. USA 2002, 99:1229-1234.
114. Lundin M., Nordling S., Lundin J., Isola J., Wiksten J.P., Haglund C. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 2005, 68:306-313.
115. Maeda T., Alexander C.M., Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004, 64:612-621.
116. Maeda T., Desouky J., Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25:1408-1412.
117. Mahtouk K., Hose D., Raynaud P., Hundemer M., Jourdan M., Jourdan E., Pantesco V., Baudard M., De Vos J., Larroque M., Moehler T., Rossi J.F., Reme T., Goldschmidt H., Klein B. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007, 109:4914-4923.
118. Marynen P., Zhang J., Cassiman J.J., Van den Berghe H., David G. Partial primary structure of the 48- and 90-kilodalton core proteins of cell surface-associated heparan sulfate proteoglycans of lung fibroblasts. Prediction of an integral membrane domain and evidence for multiple distinct core proteins at the cell surface of human lung fibroblasts. J. Biol. Chem. 1989, 264:7017-7024.
119. McFall A.J., Rapraeger A.C. Characterization of the hight affinity cell-binding domain in the cell surface proteoglycan syndecan-4. J. Biol. Chem. 1998, 273:28270-28276.
120. Middleton J., Neil S., Wintle J., Clark-Lewis I., Moore H., Lam C., Auer M., Hub E., Rot A. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997, 91:385-395.
121. Midwood K.S., Valenick L.V., Hsia H.C., Schwarzbauer J.E. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol. Biol. Cell 2004, 15:5670-5677.
122. Morgan M.R., Humphries M.J., Bass M.D. Synergistic control of cell adhesion by integrins and syndecans. Nat. Rev. Mol. Cell Biol. 2007, 8:957-969.
123. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882.
124. Nikolova V., Koo C.Y., Ibrahim S.A., Wang Z., Spillmann D., Dreier R., Kelsch R., Fischgrabe J., Smollich M., Rossi L.H., Sibrowski W., Wulfing P., Kiesel L., Yip G.W., Gotte M. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30:397-407.
125. O'Callaghan R.J., Callegan M.C., Moreau J.M., Green L.C., Foster T.J., Hartford O.M., Engel L.S., Hill J.M. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect. Immun. 1997, 65:1571-1578.
126. Ogawa T., Tsubota Y., Hashimoto J., Kariya Y., Miyazaki K. The short arm of laminin gamma2 chain of laminin-5 (laminin-332) binds syndecan-1 and regulates cellular adhesion and migration by suppressing phosphorylation of integrin beta4 chain. Mol. Biol. Cell 2007, 18:1621-1633.
127. Park P.W., Pier G.B., Preston M.J., Goldberger O., Fitzgerald M.L., Bernfield M. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J. Biol. Chem. 2000, 275:3057-3064.
128. Park P.W., Reizes O., Bernfield M. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J. Biol. Chem. 2000, 275:29923-29926.
129. Park P.W., Pier G.B., Hinkes M.T., Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001, 411:98-102.
130. Park P.W., Foster T.J., Nishi E., Duncan S.J., Klagsbrun M., Chen Y. Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin. J. Biol. Chem. 2004, 279:251-258.
131. Pierce A., Lyon M., Hampson I.N., Cowling G.J., Gallagher J.T. Molecular cloning of the major cell surface heparan sulfate proteoglycan from rat liver. J. Biol. Chem. 1992, 267:3894-3900.
132. Popova T.G., Millis B., Bradburne C., Nazarenko S., Bailey C., Chandhoke V., Popov S.G. Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors. BMC Microbiol. 2006, 6:8-24.
133. Pruessmeyer J., Martin C., Hess F.M., Schwarz N., Schmidt S., Kogel T., Hoettecke N., Schmidt B., Sechi A., Uhlig S., Ludwig A. A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J. Biol. Chem. 2010, 285:555-564.
134. Purushothaman A., Chen L., Yang Y., Sanderson R.D. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 2008, 283:32628-32636.
135. Purushothaman A., Uyama T., Kobayashi F., Yamada S., Sugahara K., Rapraeger A.C., Sanderson R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115:2449-2457.
136. Rajgopal R., Butcher M., Weitz J.I., Shaughnessy S.G. Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway. J. Biol. Chem. 2006, 281:20780-20787.
137. Ramani V.C., Yang Y., Ren Y., Nan L., Sanderson R.D. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J. Biol. Chem. 2011, 286:6490-6499.
138. Rapraeger A.C., Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells. A putative membrane proteoglycan associates quantitatively with lipid vesicles. J. Biol. Chem. 1983, 258:3632-3636.
139. Rapraeger A., Jalkanen M., Bernfield M. Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells. J. Cell Biol. 1986, 103:2683-2696.
140. Rathinam R., Alahari S.K. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010, 29:223-237.
141. Rees M.D., Pattison D.I., Davies M.J. Oxidation of heparan sulphate by hypochlorite: role of N-chloro derivatives and dichloramine-dependent fragmentation. Biochem. J. 2005, 391:125-134.
142. Richards R.M., Lowy D.R., Schiller J.T., Day P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1522-1527.
143. Ridley A.J. Life at the leading edge. Cell 2011, 145:1012-1022.
144. Rops A.L., Gotte M., Baselmans M.H., van den Hoven M.J., Steenbergen E.J., Lensen J.F., Wijnhoven T.J., Cevikbas F., van den Heuvel L.P., van Kuppevelt T.H., Berden J.H., van der Vlag J. Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int. 2007, 72:1204-1215.
145. Rostand K.S., Esko J.D. Microbial adherence to and invasion through proteoglycans. Infect. Immun. 1997, 65:1-8.
146. Roy M., Marchetti D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J. Cell. Biochem. 2009, 106:200-209.
147. Rusnati M., Urbinati C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr. Pharm. Des. 2009, 15:2946-2957.
148. Sanderson R.D., Borset M. Syndecan-1 in B lymphoid malignancies. Ann. Hematol. 2002, 81:125-135.
149. Sandstrom J., Carlsson L., Marklund S.L., Edlund T. The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity. J. Biol. Chem. 1992, 267:18205-18209.
150. Saphire A.C., Bobardt M.D., Zhang Z., David G., Gallay P.A. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J. Virol. 2001, 75:9187-9200.
151. Sarrazin S., Bonnaffe D., Lubineau A., Lortat-Jacob H. Heparan sulfate mimicry: a synthetic glycoconjugate that recognizes the heparin binding domain of interferon-gamma inhibits the cytokine activity. J. Biol. Chem. 2005, 280:37558-37564.
152. Saunders S., Bernfield M. Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J. Cell Biol. 1988, 106:423-430.
153. Saunders S., Jalkanen M., O'Farrell S., Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J. Cell Biol. 1989, 108:1547-1556.
154. Schellings M.W., Vanhoutte D., van Almen G.C., Swinnen M., Leenders J.J., Kubben N., van Leeuwen R.E., Hofstra L., Heymans S., Pinto Y.M. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension 2010, 55:249-256.
155. Schmidtchen A., Frick I., Björck L. Dermatan sulfate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin. Mol. Microbiol. 2001, 39:708-713.
156. Seidel C., Borset M., Hjertner O., Cao D., Abildgaard N., Hjorth-Hansen H., Sanderson R.D., Waage A., Sundan A. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000, 96:3139-3146.
157. Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I.M., Abildgaard N., Waage A., Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000, 95:388-392.
158. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25:101-137.
159. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 2003, 77:13125-13135.
160. Shaughnessy S.G., Walton K.J., Deschamps P., Butcher M., Beaudin S.M. Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. Cytokine 2002, 20:78-85.
161. Shukla D., Liu J., Blaiklock P., Shworak N.W., Bai X., Esko J.D., Cohen G.H., Eisenberg R.J., Rosenberg R.D., Spear P.G. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999, 99:13-22.
162. Smith A.J., Schacker T.W., Reilly C.S., Haase A.T. A role for syndecan-1 and claudin-2 in microbial translocation during HIV-1 infection. J. Acquir. Immune Defic. Syndr. 2010, 55:306-315.
163. Spillmann D. Heparan sulfate: anchor for viral intruders?. Biochimie 2001, 83:811-817.
164. Stanford K.I., Bishop J.R., Foley E.M., Gonzales J.C., Niesman I.R., Witztum J.L., Esko J.D. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Invest. 2009, 119:3236-3245.
165. Stanley M.J., Stanley M.W., Sanderson R.D., Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am. J. Clin. Pathol. 1999, 112:377-383.
166. Stepp M.A., Gibson H.E., Gala P.H., Iglesia D.D., Pajoohesh-Ganji A., Pal-Ghosh S., Brown M., Aquino C., Schwartz A.M., Goldberger O., Hinkes M.T., Bernfield M. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J. Cell Sci. 2002, 115:4517-4531.
167. Stepp M.A., Liu Y., Pal-Ghosh S., Jurjus R.A., Tadvalkar G., Sekaran A., Losicco K., Jiang L., Larsen M., Li L., Yuspa S.H. Reduced migration, altered matrix and enhanced TGFbeta1 signaling are signatures of mouse keratinocytes lacking Sdc1. J. Cell Sci. 2007, 120:2851-2863.
168. Stepp M.A., Daley W.P., Bernstein A.M., Pal-Ghosh S., Tadvalkar G., Shashurin A., Palsen S., Jurjus R.A., Larsen M. Syndecan-1 regulates cell migration and fibronectin fibril assembly. Exp. Cell Res. 2010, 316:2322-2339.
169. Su G., Blaine S.A., Qiao D., Friedl A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 2007, 282:14906-14915.
170. Su G., Blaine S.A., Qiao D., Friedl A. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res. 2008, 68:9558-9565.
171. Sun X., Mosher D.F., Rapraeger A. Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J. Biol. Chem. 1989, 264:2885-2889.
172. Sun H., Berquin I.M., Owens R.T., O'Flaherty J.T., Edwards I.J. Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 2008, 68:2912-2919.
173. Tiwari V., O'Donnell C., Copeland R.J., Scarlett T., Liu J., Shukla D. Soluble 3-O-sulfated heparan sulfate can trigger herpes simplex virus type 1 entry into resistant Chinese hamster ovary (CHO-K1) cells. J. Gen. Virol. 2007, 88:1075-1079.
174. Vanhoutte D., Schellings M.W., Gotte M., Swinnen M., Herias V., Wild M.K., Vestweber D., Chorianopoulos E., Cortes V., Rigotti A., Stepp M.A., Van de Werf F., Carmeliet P., Pinto Y.M., Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007, 115:475-482.
175. Vollmer P., Walev I., Rose-John S., Bhakdi S. Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. Infect. Immun. 1996, 64:3646-3651.
176. Vuoriluoto K., Jokinen J., Kallio K., Salmivirta M., Heino J., Ivaska J. Syndecan-1 supports integrin alpha2beta1-mediated adhesion to collagen. Exp. Cell Res. 2008, 314:3369-3381.
177. Walev I., Vollmer P., Palmer M., Bhakdi S., Rose-John S. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc. Natl. Acad. Sci. USA 1996, 93:7882-7887.
178. Walev I., Tappe D., Glubins E., Bhakdi S. Streptolysin O-permeabilized granulocytes shed L-selectin concomitantly with ceramide generation via neutral sphingomyelinase. J. Leukoc. Biol. 2000, 68:865-872.
179. Watson A.J., Chu S., Sieck L., Gerasimenko O., Bullen T., Campbell F., McKenna M., Rose T., Montrose M.H. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 2005, 129:902-912.
180. Webb L.M.C., Ehrengruber M.U., Clark-Lewis I., Baggiolini M., Rot A. Binding of heparan sulfate or heparin enhances neutrophil responses to IL-8. Proc. Natl. Acad. Sci. USA 1993, 90:7158-7162.
181. Wiksten J.P., Lundin J., Nordling S., Lundin M., Kokkola A., von Boguslawski K., Haglund C. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int. J. Cancer 2001, 95:1-6.
182. Woods D.E., Cryz S.J., Friedman R.L., Iglewski B.H. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect. Immun. 1982, 36:1223-1228.
183. WuDunn D., Spear P.G. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 1989, 63:52-58.
184. Xu J., Park P.W., Kheradmand F., Corry D.B. Endogenous attenuation of allergic lung inflammation by syndecan-1. J. Immunol. 2005, 174:5758-5765.
185. Yang Y., Yaccoby S., Liu W., Langford J.K., Pumphrey C.Y., Theus A., Epstein J., Sanderson R.D. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002, 100:610-617.
186. Yang Y., Macleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., Sawyer J., Li J.P., Zcharia E., Vlodavsky I., Sanderson R.D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
187. Yang N., Mosher R., Seo S., Beebe D., Friedl A. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am. J. Pathol. 2011, 178:325-335.
188. Yeaman C., Rapraeger A.C. Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J. Cell Biol. 1993, 122:941-950.